[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangxi Provincial Cancer Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":299},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,70,102,123,151,174,200,223,245,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100537378","phase-3-maintenance-therapy-with-toripalimab-and-capecitabine-versus-capecitabine-alone-in-high-risk-nasopharyngeal-carcinoma-100537378",false,"NCT06277050","Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma","Maintenance Therapy With Toripalimab Combined With Capecitabine Versus Maintenancetherapy With Capecitabine Alone in High-risk Nasopharyngeal Carcinoma: a Multicenter, Prospective, Randomized Phase III Clinical Trial (NPC-ICMB)","Inclusion Criteria:\n\n1. Pathologically confirmed nasopharyngeal carcinoma;\n2. High-risk nasopharyngeal cancer meets one of three points: a. TanyN3M0; b. High-grade rENE, coalescent nodal or invasion of surrounding structures (muscle, skin, nerves, etc.); c. Detectable EBV DNA after 2 cycles of induction chemotherapy.\n\n3.18-70 years old, both genders; 4. ECOG≤1; 5. Received 2-3 cycles of induction chemotherapy and concurrent chemoradiotherapy (intensity-modulated radiotherapy); 6. Patients must have adequate organ function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment) as determined by: Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Platelet count ≥ 75×109\u002FL; Hemoglobin ≥ 9 g\u002FdL; serum total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), (for subjects with liver metastases, TBIL ≤3×ULN; ALT and AST≤5×ULN); Creatinine ≤1.5×ULN or creatinine clearance rate≥50 ml\u002Fmin (Cockcroft-Gault formula); serum albumin ≥28 g\u002FL.\n\n7\\. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative; 8. Written informed consent;\n\nExclusion Criteria:\n\n1. Recurrent or distant metastatic nasopharyngeal carcinoma.\n2. History of malignant tumors (except cured basal cell carcinoma or uterine cervical carcinoma in situ) within the last 5 years.\n3. Has received any prior radiotherapy (RT) or systemic anti-cancer therapy including investigational agents for NPC\n4. Has received prior therapy with an anti-PD-1 mab.\n5. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n\n   Note: Patients with the following diseases are not excluded and may proceed to further screening:\n   1. Controlled Type I diabetes\n   2. Hypothyroidism (provided it is managed with hormone replacement therapy only)\n   3. Controlled celiac disease\n   4. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia) Any other disease that is not expected to recur in the absence of external triggering factors.\n6. Any condition that required systemic treatment with either corticosteroids (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the start of the study。\n\n   Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:\n   1. Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)\n   2. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption\n   3. Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)。\n7. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n8. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n\n   1. Severe infections within 4 weeks before the start of the study, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n   2. Received therapeutic oral or intravenous antibiotics within 2 weeks before start of the study.\n9. A known history of HIV infection\n10. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is \\>1000 IU\u002FmL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C1000 IU\u002FmL), and cured hepatitis C patients can be enrolled.\n11. Any major surgical procedure requiring general anaesthesia ≤28 days before start of study。\n12. Prior allogeneic stem cell transplantation or organ transplantation.\n13. Any of the following cardiovascular risk factors:\n\n    1. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before start of study\n    2. Pulmonary embolism ≤28 days before start of study\n    3. Any history of acute myocardial infarction ≤6 months before start of study\n    4. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study\n    5. Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before start of study\n    6. Any history of cerebrovascular accident ≤6 months before start of study\n    7. Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before start of study\n    8. Any episode of syncope or seizure ≤28 days before start of study.\n14. A history of severe hypersensitivity reactions to toripalimab, capecitabine and\u002For any of its excipients.\n15. Has received any herbal medicine used to control cancer within 14 days of the start of study\n16. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities)\n17. Concurrent participation in another therapeutic clinical study\n18. Emotional disturbance or mental illness\n19. Refusal or inability to sign informed consent","ALL","18 Years","70 Years",{"count":20,"type":21},264,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","N3 classification, rENE positivity is a high-risk type of locally advanced nasopharyngeal carcinoma. EBV DNA remaining at detectable levels after induction chemotherapy is also a characteristic of high-risk nasopharyngeal carcinoma. Based on the available evidence, patients with high-risk nasopharyngeal carcinoma are recommended to receive oral maintenance therapy to reduce the risk of failure.\n\nThe purpose of this study was to conduct a prospective, multicenter, randomized phase III clinical trial to determine whether maintenance therapy with triprilimab combined with capecitabine is better than maintenance therapy with capecitabine alone in high-risk nasopharyngeal carcinoma (N3+, rENE+, Detectable EBV DNA after 2 cycles of induction chemotherapy).",[27,28,29],"Nasopharyngeal Carcinoma","High-Risk Cancer","Maintenance Therapy","RECRUITING","2026-05-13",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":34},"2024-03-07",{"date":38,"type":21},"2031-02-20",{"name":40,"class":41},"Jiangxi Provincial Cancer Hospital","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100635991","phase-3-topical-chlorhexidine-spray-for-the-prevention-of-acute-radiation-dermatitis-in-patients-with-nasopharyngeal-carcinoma-100635991","NCT07559877","Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:","Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma: A Phase III Randomized Double-Blind Single-Center Trial","Inclusion Criteria:\n\nHistologically or cytologically confirmed nasopharyngeal carcinoma. Clinical stage II-III disease with N≥1, according to the UICC\u002FAJCC 9th edition. Planned to receive first-course definitive chemoradiotherapy, with a total radiotherapy dose of 60-70 Gy.\n\nAble to communicate and complete study assessments. Willing to participate and able to provide written informed consent. Eligible based on baseline assessments performed before chemoradiotherapy.\n\nExclusion Criteria:\n\n* History of or current psychiatric disorder, cognitive impairment, or other severe organic disease.\n\nPresence of another concomitant malignancy. Receipt of any other prophylactic intervention for radiation dermatitis. Pre-existing skin disease before chemoradiotherapy. Known hypersensitivity or allergy to chlorhexidine.","75 Years",{"count":52,"type":21},148,[24],"This study investigated the effects of topical chlorhexidine spray on the incidence, severity, and quality of life during radiotherapy in nasopharyngeal carcinoma patients.",[56],"Nasopharangeal Cancer",[58,59,60],"Radiation Dermatitis Acute","Nasoharyngeal carcinoma","chlorhexidine","2026-04-23",{"date":63,"type":34},"2026-04-30",{"date":65,"type":21},"2026-04-01",{"date":67,"type":21},"2027-09-30",{"name":40,"class":41},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100635453","pseudomembrane-removal-for-post-rt-nasopharyngeal-necrosis-100635453","NCT07552883","Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis","Endoscopic Nasopharyngeal Pseudomembrane Removal for Prevention of Radiation-Induced Nasopharyngeal Necrosis After Re-irradiation in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Multicenter Interventional Study","EPoRN","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n* Age between 18 and 80 years.\n* ECOG performance status ≤ 2.\n* Prior radical radiotherapy with total dose ≥ 66 Gy.\n* Imaging or histopathology confirmed local recurrence and\u002For retropharyngeal lymph node recurrence, with or without cervical lymph node recurrence.\n* Re-irradiation with single dose \\\u003C 2.3 Gy and total dose ≥ 50 Gy.\n* Presence of pseudomembrane reaction on nasopharyngeal mucosa during or after re-irradiation.\n* Expected survival \\> 1 year.\n* Induction chemotherapy, immunotherapy, concurrent chemotherapy, adjuvant chemotherapy, or radiotherapy alone are all permitted.\n\nExclusion Criteria:\n\n* History of other malignancies within the past 5 years, except cured non-melanoma skin cancer or carcinoma in situ of the cervix.\n* Severe uncontrolled systemic diseases (e.g., uncontrolled infection, severe cardiovascular disease, uncontrolled diabetes).\n* Pregnant or breastfeeding women.\n* Known allergy to any equipment or medication used during endoscopy.\n* Inability to tolerate endoscopic procedure due to anatomical or medical reasons.\n* Concurrent participation in another interventional clinical trial.\n* Any condition that, in the investigator's judgment, would interfere with study compliance or outcome assessment.","80 Years",{"count":80,"type":21},40,[82],"NA","This study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-arm, multicenter interventional study. Participants with recurrent nasopharyngeal carcinoma who develop pseudomembrane reaction during or after re-irradiation will receive endoscopic pseudomembrane removal. Based on published literature, the 2-year incidence of radiation-induced nasopharyngeal necrosis after re-irradiation is approximately 40%. This study expects to reduce the incidence to 20%. The primary outcome measure is the 2-year incidence of nasopharyngeal necrosis after re-irradiation. Secondary outcome measures include: necrosis-free survival, overall survival, progression-free survival, local regional recurrence-free survival, distant metastasis-free survival, as well as safety and adverse events. A total of 40 participants will be enrolled from multiple hospitals in China.",[85,86,87],"Nasopharyngeal Carcinoma (NPC)","Radiation Injuries","Necrosis",[89,90,91,92,93],"recurrent NPC","re-RT","radiation necrosis","pseudomembrane","endoscopy","NOT_YET_RECRUITING","2026-04-20",{"date":97,"type":34},"2026-04-27",{"date":63,"type":21},{"date":100,"type":21},"2031-04-30",{"name":40,"class":41},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100621258","limited-target-volume-radiotherapy-after-glioblastoma-surgery-100621258","NCT07368283","Limited Target Volume Radiotherapy After Glioblastoma Surgery","A Single-arm Phase II Non-inferiority Clinical Study of Limited Target Volume Radiotherapy After Glioblastoma Surgery","Inclusion Criteria:\n\n* Aged between 18 and 70 years.\n* Diagnosed with glioblastoma by surgical pathology, with the extent of resection achieving maximal safe resection.\n* Within 2 to 6 weeks after surgery\n* In good physical condition with a Karnofsky Performance Status (KPS) score ≥ 60.\n* Hematological, hepatic, and renal functions are essentially normal.\n* Signed informed consent, willing to undergo treatment and follow-up as stipulated in the study protocol.\n\nExclusion Criteria:\n\n* Prior history of cranial radiotherapy or other malignant tumors.\n* Severe dysfunction of vital organs (e.g., heart, liver, kidneys) that precludes tolerance to radiotherapy.\n* Active infection, immune system disorders, or other serious chronic diseases.\n* Pregnancy or lactation.\n* Psychiatric disorders or severe cognitive impairment that compromises the ability to cooperate with treatment and follow-up.",{"count":110,"type":21},79,[82],"Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity. Previous retrospective analysis by investigators revealed that local recurrences of glioblastoma are predominantly confined to a narrow margin around the original lesion: 98.3% of recurrences occurred within 0.5 cm of the original T2-FLAIR abnormality, 94.8% within 1 cm of the original T1-enhanced region. These findings have been cited in the ESTRO-EANO treatment guidelines. Building on this evidence, investigators plan to conduct a single-arm, phase II clinical trial to systematically evaluate the efficacy and safety of a 1 cm radiotherapy target volume in post-operative glioblastoma patients.Eligible patients with glioblastoma who have undergone surgical resection will be selected to receive limited-field radiotherapy. The target volume will be defined based on the postoperative MRI enhancing lesion: a 1 cm margin will be added to form the clinical target volume (CTV), followed by a further 0.3 cm margin to create the planning target volume (PTV). A total dose of 60 Gy will be delivered in 30 fractions (2 Gy per fraction, 5 fractions per week). Concurrent and adjuvant chemotherapy will be administered per standard guidelines. The primary efficacy endpoints are the 6-month progression-free survival rate and the incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher. Secondary endpoints include overall survival, patterns of recurrence, neurocognitive function, and quality of life.",[114],"Glioblastoma (GBM)","2026-01-28",{"date":117,"type":34},"2026-01-30",{"date":119,"type":21},"2026-01",{"date":121,"type":21},"2030-12",{"name":40,"class":41},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":69},"100614297","phase-2-induction-high-low-dose-radiotherapy-plus-anti-pd-1-followed-by-definitive-radiotherapy-in-recurrent-nasopharyngeal-carcinoma-single-arm-phase-ii-100614297","NCT07277764","Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)","Induction Therapy With High-Low Dose Radiotherapy Combined With Anti-PD-1 Monoclonal Antibody Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Single-Center Phase II Trial","REDEFINE","Inclusion Criteria：\n\nHistologically confirmed non-keratinizing NPC (WHO II\u002FIII); local (± regional) recurrence ≥1 year after prior radical therapy; surgery-ineligible;\n\nrT2-rT4 (AJCC 8th); ECOG 0-1;\n\nAdequate organ function (hematologic, hepatic, renal, coagulation per protocol thresholds);\n\nContraception requirements per protocol; signed informed consent.\n\nExclusion Criteria：\n\nDistant metastasis at recurrence; active necrosis at recurrence; active\u002Fprevious autoimmune disease; prior PD-1\u002FPD-L1 therapy; uncontrolled comorbidities; active infections (HBV\u002FHCV\u002FHIV criteria per protocol); interstitial lung disease\u002Fpneumonitis; pregnancy\u002Flactation; other protocol-specified exclusions.",{"count":132,"type":21},23,[134],"PHASE2","This single-arm, single-center phase II trial evaluates the safety and efficacy of a non-continuous radio-immunotherapy strategy for recurrent nasopharyngeal carcinoma (NPC) unsuitable for surgery. Induction consists of three fractions of low-dose radiotherapy (1.5 Gy ×3) plus high-dose boosts (5 Gy ×3 to tumor core with carotid\u002Fmucosal sparing) combined with anti-PD-1 (240 mg IV on Day 1 and Day 22). After a 21-28-day interval, definitive IMRT (2 Gy ×28, 5 days\u002Fweek) is delivered without concurrent immunotherapy to minimize immune damage. Anti-PD-1 maintenance (240 mg IV Q3W) starts within 2 weeks after radiotherapy for up to 12 months or until progression\u002Ftoxicity. The primary endpoint is ORR at 3 months post-radiotherapy; secondary endpoints include 3-year OS, 3-year PFS, safety (NCI-CTCAE v5.0), and quality of life (EORTC QLQ-C30). Key eligibility: histologically confirmed non-keratinizing NPC (WHO II\u002FIII), rT2-rT4, ECOG 0-1, adequate organ function.",[85,137],"Recurrent Nasopharyngeal Neoplasms",[89,139,140,141,142],"re-irradiation","high-low dose radiotherapy","induction radio-immunotherapy","PD-1 inhibitor","2025-11-30",{"date":145,"type":34},"2025-12-11",{"date":147,"type":34},"2025-10-10",{"date":149,"type":21},"2029-12-31",{"name":40,"class":41},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":69},"100599553","phase-2-effect-of-nutritional-management-on-patients-with-concurrent-chemoradiotherapy-for-nasopharyngeal-carcinoma-100599553","NCT07085988","Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma","Nutritional Management During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma Has an Impact on Immunonutritional Status and Therapeutic Phase Toxicity and Prognostic Effects","Inclusion Criteria:\n\n* 1.Patients with nasopharyngeal carcinoma confirmed by histopathology;2.Clinical stage stage II-IVa,Concurrent chemoradiotherapy is included in the definitive treatment regimen;3.Age ≥ 18 years, male or female;4.PG-SGA score of 0-8 before radiotherapy;5.KPS score ≥ 60 or ECOG score ≤3;6.Nutritional supplementation can be given by mouth or enterally;7.Patients sign a formal informed consent form to indicate that they understand that this study complies with hospital policies;8.Serum hemoglobin ≥ 90 g\u002FL, platelet ≥ 100×109\u002FL, absolute neutrophil count ≥ 1.5×109\u002FL;9.serum creatinine ≤1.25 times ULN or creatinine clearance ≥60 mL\u002Fmin;10.Serum bilirubin ≤ 1.5-fold ULN, AST (SGOT) and ALT (SGPT) ≤ 2.5-fold ULN, and alkaline phosphatase ≤ 5-fold ULN.\n\nExclusion Criteria:\n\n* 1.Have a second primary tumor;2.Those who do not receive concurrent chemoradiotherapy;3.Comorbid diabetes mellitus, or history of severe endocrine and metabolic diseases;4.Those who are allergic to oral nutritional meal replacements.",{"count":159,"type":21},109,[134],"Nasopharyngeal carcinoma (NPC) is a malignant tumor that develops in the nasopharyngeal mucosal epithelium. Due to the disease itself and the impact of anti-tumor therapy, malnutrition has become a common clinical complication in patients with NPC, among which NPC patients receiving concurrent chemoradiotherapy are one of the groups with the highest incidence of malnutrition, and malnutrition seriously affects the prognosis of NPC patients. Nutritional management throughout the course has a positive impact on the prognosis and life management of NPC patients. As an immune-enhancing oral nutritional preparation, it is helpful to maintain the weight and immune function of patients with nasopharyngeal carcinoma during concurrent chemoradiotherapy, reduce the degree of treatment-related side effects during concurrent chemoradiotherapy for nasopharyngeal carcinoma, and delay the occurrence of acute side effects. The purpose of this study was to investigate the effect of rapid rapid rapid improvement of patients' immune status during concurrent chemoradiotherapy, and to further evaluate its impact on patients' weight, prognosis, treatment-related toxic side effects, and quality of life. In this study, 109 patients with nasopharyngeal carcinoma who received concurrent chemoradiotherapy in our hospital are planned to be included, and all patients in this group will be given oral tachyphin at a standard dose from the first day of radiotherapy. The nutritional immune status of the patient was assessed at different points during the treatment period.",[85],[27,164,165],"Concurrent chemoradiotherapy","Immunonutrition Lymphocyte count","2025-07-24",{"date":168,"type":34},"2025-07-25",{"date":170,"type":34},"2025-01-01",{"date":172,"type":21},"2028-12-31",{"name":40,"class":41},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":69},"100573896","phase-3-prophylactic-radiotherapy-optimization-for-enhanced-thyroid-function-protection-in-npc-100573896","NCT06752239","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC","Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial","PROTECT-NPC","Inclusion Criteria:\n\n1\\. Male or female, aged 18-70 years; 2. Pathologically confirmed nasopharyngeal carcinoma; 3. No positive lymph nodes in unilateral or bilateral regions III and IVa; 4. Clinical stage I-IVa (AJCC\u002FUICC 8th edition), with no evidence of distant metastasis; 5. Normal thyroid function; 6. ECOG performance status of 0-1; 7. Treatment-naïve patients who have not received any prior antitumor therapy; 6. No contraindications to radiotherapy or chemotherapy; 9. Adequate organ function, meeting the following criteria: Hematologic criteria: WBC ≥ 4.0 × 10⁹\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, HGB ≥ 90 g\u002FL (no transfusion, blood products, or hematopoietic growth factors used within the past 7 days); Biochemical criteria: ALT and AST \\\u003C 1.5 × ULN, ALP \\\u003C 2.5 × ULN, total bilirubin \\\u003C ULN, BUN and creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n\n10\\. Voluntarily agreed to participate in the study, signed the informed consent form, demonstrated good compliance, and agreed to follow-up.\n\nExclusion Criteria:\n\n1. History of other malignant tumors (excluding basal cell carcinoma\u002Fsquamous cell carcinoma of the skin or cervical carcinoma in situ);\n2. History of radiotherapy (excluding radiotherapy outside the planned target area for conditions such as melanoma);\n3. History of neck surgery;\n4. Any severe comorbidities that may pose risks to the study or affect compliance, such as unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose \\> 1.5 × ULN), or psychiatric disorders;\n5. History of hyperthyroidism, hypothyroidism, or immune-related thyroid disorders;\n6. Other family or social factors, as judged by the investigator, may force the study's early termination, compromise patient safety, or affect the collection of trial data.",{"count":183,"type":21},474,[24],"This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation radiotherapy (control group) in the prophylactic irradiation of neck lymphatic drainage areas III\u002FIVa in nasopharyngeal carcinoma. The study evaluates the incidence of primary hypothyroidism, quality of life, and adverse events between the two groups.",[27,187,188,189,190],"Quality of Life","Thyroid Diseases","Radiotherapy Side Effect","Radiotherapy",[27,187,192,190],"Thyroid Function Protection","2025-04-08",{"date":195,"type":34},"2025-04-10",{"date":170,"type":34},{"date":198,"type":21},"2031-12-31",{"name":40,"class":41},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":69},"100536045","phase-2-anti-pd1-monoclonal-antibody-combined-with-nimotuzumab-and-capecitabine-in-patients-with-first-line-platinum-resistant-recurrentmetastatic-nasopharyngeal-carcinoma-100536045","NCT06259721","Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","Efficacy and Safety of Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent\u002FMetastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Multi-center Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed with recurrent or metastatic nasopharyngeal carcinoma which is not amenable to curative treatment with surgery and\u002For radiation therapy. If the patient refuses biopsy of metastatic lesions, those diagnosed with metastasis based on imaging evidence and clinical evidence can be enrolled.\n2. Have failed for first-line platinum-based chemotherapy. Previously received first-line platinum-based chemotherapy for recurrent or metastatic disease and had disease progression during or after treatment; or recurrence and metastases within 6 months after treatment of platinum-based chemoradiation.\n3. Age ≥ 18 years and ≤ 75 years, both genders.\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n5. The life expectancy of at least 3 months.\n6. Patients must have at least 1 lesion that is measurable using RECIST v1.1 criteria.\n7. Patients must have adequate organ function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment) as determined by:\n\n   Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Platelet count ≥ 75×109\u002FL; Hemoglobin ≥ 9 g\u002FdL; serum total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), (for subjects with liver metastases, TBIL ≤3×ULN; ALT and AST≤5×ULN); Creatinine ≤1.5×ULN or creatinine clearance rate≥50 ml\u002Fmin (Cockcroft-Gault formula); serum albumin ≥28 g\u002FL; Thyroid-stimulating hormone (TSH) levels ≤1×ULN (however, patients with free Triiodothyronine \\[FT3\\] or free Thyroxine \\[FT4\\] levels ≤1× ULN may be enrolled); INR, APTT≤1.5 x ULN.\n8. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative.\n9. Written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Those with a history of severe immediate allergy to any drugs used in this study; 2. Patients who have previously received anti-EGFR monoclonal antibodies (nitolizumab, cetuximab) and anti-PD-1 monoclonal antibodies.\n\n  3\\. Combined with other malignant tumors; 4. Any of the following conditions exist within 6 months before screening: myocardial infarction, severe\u002Funstable angina, coronary artery\u002Fperipheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident, transient cerebral ischemia Paroxysmal or symptomatic pulmonary embolism. Patients with known coronary artery disease, congestive heart failure that does not meet the above criteria, or left ventricular ejection fraction \\\u003C50% must be treated with an optimized and stable medical regimen as determined by the treating physician, who may consult a cardiologist if appropriate; 5. Patients who have received any of the following treatments:\n\n  (1) Have received any investigational drugs within 4 weeks before using the investigational drugs for the first time; (2) Use of large amounts of glucocorticoids or other immunosuppressants (including but not limited to prednisone, dexamethasone, azathioprine, methotrexate, thalidomide and anti-tumor necrosis factor within 4 weeks before treatment (drugs against TNF), or subjects who require hormonal therapy during clinical trials. Other special circumstances need to be communicated with the sponsor. In the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone replacement at doses \\>10 mg\u002Fday prednisone therapeutic dose are allowed; (4) Those who have received anti-tumor vaccines or have received live vaccines within 4 weeks before the first administration of the study drug; (5) Have undergone major surgery or serious trauma within 4 weeks before using the study drug for the first time; (6) Enroll in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up; 6. Patients with active autoimmune diseases or a history of autoimmune diseases that may relapse\n\nNote: Patients with the following diseases are not excluded and can enter further screening:\n\n1. Controlled type 1 diabetes\n2. Hypothyroidism (if it can be controlled with hormone replacement therapy alone)\n3. Skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, alopecia)\n4. Any other disease that is not expected to recur in the absence of external triggers 7. Active infections, including tuberculosis, hepatitis B, hepatitis C and human immunodeficiency virus. Patients with positive HBV surface antigen (HBsAg) but HBV DNA \\\u003C1000 copies\u002FmL are eligible to participate in this study; patients with positive HCV antibody test results can only participate if the HCV RNA polymerase chain reaction test result is negative. Selected for this study; 8. History of idiopathic pulmonary fibrosis, drug-induced pneumonia, organizing pneumonia (bronchiolitis obliterans), idiopathic pneumonia or evidence of active pneumonia on chest CT scan during screening; 9. No capacity for civil conduct or limited capacity for civil conduct; 10. Drug abuse or alcohol addiction, the patient has physical or mental illness, and the researcher believes that the patient cannot fully or fully understand the possible complications of this study; 11. Other serious acute or chronic medical conditions that may increase the risks related to the treatment of the research protocol, or may interfere with the interpretation of the research results and (according to the investigator's judgment) may make the patient unfit to participate in this study (including immune colitis, inflammatory colitis, Enteropathy, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including dementia and epilepsy, suicidal ideation or behavior recently, within the past year, or active) or abnormal laboratory tests; 12. Previously diagnosed with immunodeficiency or known diseases related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); 13. Pregnant or lactating female patients, male or female patients with childbearing potential but unwilling or unable to use contraception during the entire study period and for at least 1 year after the end of the treatment plan; 14. Those with recurrent nasopharyngeal carcinoma are suitable for surgical treatment.",{"count":208,"type":21},22,[134],"The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.",[27],[27,213,214,215],"anti-PD1 antibody","Nimotuzumab","Capecitabine","2024-03-06",{"date":36,"type":34},{"date":219,"type":34},"2024-02-10",{"date":221,"type":21},"2026-08-09",{"name":40,"class":41},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":69},"100530121","the-prognostic-value-of-the-degree-of-pathological-response-of-induction-chemotherapy-for-npc-100530121","NCT06182657","The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC","The Prognostic Value of the Degree of Pathological Response at One Cycle of Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinon-a Prospective Observational Study","Inclusion Criteria:\n\n1. Ability to sign informed consent\n2. Age \\> 18 years at time of study entry\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)\n4. Histological confirmation of NPC (regardless if EBER positive or negative)\n5. Locally advanced NPC, UICC stage III-IVa\n6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n2. Distant metastases\n3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.\n4. History of another primary malignancy\n5. Female patients who are pregnant\n6. Known allergy or hypersensitivity to any drugs\n7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.",{"count":231,"type":21},300,"OBSERVATIONAL","This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.",[27,235,236],"Pathologic Complete Response","Tumor Microenvironment","2024-02-07",{"date":239,"type":34},"2024-02-08",{"date":241,"type":34},"2024-01-01",{"date":243,"type":21},"2029-06-30",{"name":40,"class":41},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":69},"100458627","phase-2-anlotinib-hydrochloride-capsules-combined-with-tqb2450-injection-in-esophageal-squamous-cell-carcinoma-patients-100458627","NCT05252078","Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients as Postoperative Adjuvant Therapy","ALTER-E005","Inclusion Criteria:\n\n* Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.\n* ≥ 18 years old.\n* ECOG performance status of 0-1\n* Patients with esophageal squamous cell carcinoma pathologically diagnosed as T1-2N1-3M0 or T3-4NanyM0.\n* Patients received radical (R0) resection of squamous cell carcinoma with no recurrence in imaging examination within 6-12 weeks after surgery, and need adjuvant therapy assessed by the researchers.\n* Laboratory tests must be met:\n* Neutrophils count =\u002F\\> 1.5 x 109\u002FL, platelets count =\u002F\\> 75 x 109\u002FL, Hb =\u002F\\> 90 g\u002FL, WBC =\u002F\\> 3 x 109\u002FL.\n* total bilirubin =\u002F\\\u003C 1.5 x ULN, ALT and AST =\u002F\\\u003C 2.5 x ULN.\n* Creatinine =\u002F\\\u003C 1.5 x ULN.\n* APTT, INR, PT =\u002F\\\u003C 1.5 x ULN.\n* TSH =\u002F\\\u003C ULN.\n* Myocardial enzymes in the normal range.\n* LVEF =\u002F\\> 50%.\n\nExclusion Criteria:\n\n* Patients received other antitumor adjuvant therapy after surgical resection.\n* Concurrent malignancy (except cured basal cell carcinoma of the skin).\n* Patients was diagnosed cervical esophageal carcinoma.\n* Patients who have received prior targeted therapy (anti-VEGF\u002FVEGFR) or immunity therapy (anti-PD-1\u002FPD-L1\u002FCTLA-4).\n* Patients who are allergic to other monoclonal antibodies.\n* Patients with a history of immunodeficiency (or active autoimmue disease), or other acquired congenital immunodeficiency diseases.\n* Immunosuppressant, systemic, or absorbable local hormone therapy (\\> 10mg\u002F day of prednisone or other equivalent hormone) is required for immunosuppression and continued within 2 weeks of initial administration.\n* Patients with multiple factors affecting oral administration.\n* Uncontrolled pleural effusion, pericardial effusion or ascites that requires repeated drainage.\n* With bleeding tendency. Patients with any bleeding or bleeding event CTC AE grade 3 in the 4 weeks prior to initial administration. The presence of digestive diseases or active bleeding of unresected tumors, or other conditions that the investigator determined which could lead to gastrointestinal bleeding or perforation.\n* Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.\n* Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg).\n* Patients with myocardial infarction, myocardial ischemia, arrhythmias with poor control (including QTC interval male \\> 450 ms, female\\> 470 ms) and cardiac insufficiency of grade II according to NYHA standard.\n* Active or uncontrolled severe infection (≥ CTC AE Grade 2 infection).\n* HIV test positive.\n* Proteinuria =\u002F\\>2+ and confirmed 24-hour urinary protein quantification \\> 1.0 g.\n* Vaccination with prophylactic or attenuated vaccine within 4 weeks prior to initial administration.\n* According to the investigators' judgment, there are factors that endanger patient or prevent patients from completing the study.",{"count":254,"type":21},30,[134],"This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).",[258,259,260,261,262,263,264,265,266,267,268],"Esophageal Squamous Cell Carcinoma","Esophageal Neoplasms","Esophageal Diseases","Gastrointestinal Neoplasms","Gastrointestinal Diseases","Digestive System Neoplasms","Digestive System Diseases","Neoplasms by Site","Neoplasms by Histologic Type","Neoplasms, Squamous Cell","Carcinoma, Squamous Cell","2022-12-14",{"date":271,"type":34},"2022-12-16",{"date":273,"type":34},"2022-06-02",{"date":275,"type":21},"2026-11",{"name":40,"class":41},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":283,"minAge":17,"maxAge":50,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":69},"100399482","phase-1-a-study-of-the-efficacy-and-safety-of-camrelizumab-plus-radiotherapy-for-patients-with-early-triple-negative-breast-100399482","NCT04481763","A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","Inclusion Criteria:\n\n1. female participants aged ≥ 18 years and \\\u003C 75 years\n2. Participants with a histological or cytological diagnosis of TNBC breast cancer , defined by ER \\\u003C1%, PR \\\u003C1% and HER2 negative on IHC and\u002For non-amplified by ISH by local lab testing\n3. Gene detection for Subtypes of TNBC、PD-L1expression and TMB expression\n4. Breast-conserving therapy is planned after mastectomy 1) largest focus must measure of Primary tumor ≥ 5cm，Tumor invades breast skin and chest wall 2) Axillary lymph node metastasis≥4 3) 1 -3 lymph node metastases in stage T1-2 4) Simple mastectomy combined with axillary lymphadenectomy in stage T1-2 (axillary lymph nodes are positive, and subsequent axillary dissection is not considered)\n5. Adequate Organ Function as defined in the table below:\n\n   Absolute neutrophil count (ANC) ≥ 1500\u002FuL Platelet count ≥ 100,000\u002FuL Hemoglobin ≥5.6mmol\u002FL（9.0g\u002FdL) serum albumin ≥2.8g\u002FdL Serum creatinine ≤ ≤1.5mg\u002Fd or creatinine clearance ≥ 50mL\u002Fmin Serum Total Bilirubin ≤ 1.5 X ULN AST\\&ALT≤2.5ULN\n6. 12 lead ECG: friderica corrected QT interval (QTCF) \\\u003C 470 Ms\n7. Women of childbearing potential must have a negative urine or serum pregnancy test within 28 day prior to registration; women\u002Fmen of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 90 days after the last dose of study medication.\n8. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Known additional malignancy that is progressing or has required active treatment .\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n2. Patients with evident metastatic lesions at the time of diagnosis\n3. Has received prior therapy with an anti-PD-1, anti-PD-L1.History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n4. There are any active autoimmune diseases or a medical history of autoimmune (including, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid function Decreased. Subjects with vitiligo or adults who have had childhood asthma but have fully relieved without any intervention may be included. However, subjects who require bronchodilators for medical intervention cannot be included.)\n5. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n6. Ascites or pleural effusion with clinical symptoms, requiring therapeutic puncture or drainage\n7. Cardiac clinical symptoms or diseases that are not well controlled, such as: a. Heart Failure NYHA \\> Class Ⅱ, b. unstable angina, c. myocardial infarction within 1 year; d. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.\n8. Abnormal coagulation function (PT\\>16s, APTT\\>43s, TT\\>21s, Fbg\\\u003C2g\u002FL), with obvious bleeding tendency or undergoing thrombolytic or anticoagulant treatment\n9. History of clear tendency of gastrointestinal hemorrhage and active bleeding in unresected tumor within 3 months prior to the start of study treatment. for example, esophageal varices, gastric and duodenal active ulcer, ulcerative colitis, portal hypertension ; Or other conditions that may cause gastrointestinal bleeding and perforation determined by the researchers;\n10. Previous or current serious bleeding (bleeding \\> 30ml in 3 months), hemoptysis (fresh blood \\> 5ml in 4 weeks) or thromboembolism within 12 months (including stroke events and \u002F or transient ischemic attacks);\n11. The patient has active infection during screening period, or unexplained fever (≥38.5 °C) before first administration ( According to the judgment of the researcher, the fever caused by the tumor can be included in the group);\n12. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 4 weeks prior to the start of study treatment;\n13. Has a history of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan.\n14. Subjects with congenital or acquired immunodeficiency (such as HIV-infected), or active hepatitis (hepatitis B reference: HBsAg-positive, HBV DNA ≥ 2000 IU\u002Fml or copy number ≥ 104\u002Fml; hepatitis C reference: HCV antibody-positive.)\n15. Patients who are participating in other clinical trials or less than 1 month from the end of the previous clinical study; Patients may receive other systemic anti-tumor treatment during the study period\n16. Receive live vaccine within 4 weeks before or during the study period;\n17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n18. According to the investigator's assessment, there are other factors that may lead to the termination of the study, such as other serious diseases (including mental illness) requiring combined treatment. Any other condition and social\u002Fpsychological problems, etc., the investigator judged that the patient was not suitable for participation in the study.","FEMALE",{"count":285,"type":21},20,[287,134],"PHASE1","This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC。",[290],"Triple-Negative Breast Cancer","2020-07-21",{"date":293,"type":34},"2020-07-22",{"date":295,"type":34},"2020-07-14",{"date":297,"type":21},"2026-10-01",{"name":40,"class":41},""]